Integrating New and Emerging Targeted Therapies into the Tx Paradigm in Ovarian Cancer: Expert Strategies for Improved Patient Outcomes

A continuing medical education activity sponsored by NAMCP and AAMCN.

This activity is an archive from the live session from the 2019 Spring Managed Care Forum. If you participated in the live session, you are not eligible for continuing education credits from this archive.

This activity is valid from June 1, 2019 to August 1, 2020

Instructions for CME/CNE: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.

 

Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This presentation is supported by educational grants from
AstraZeneca LP, ImmunoGen, & Merck Sharp & Dohme Corp.

Description:
For ovarian cancer patients, the five year survival rate is only 45%. Ovarian cancer is usually found late, stage 3 or higher, where it has already spread or metastasized to other parts of the abdomen, or worse. Fortunately for patients with ovarian cancer, the treatment paradigm has greatly changed, providing more options in managing patients with ovarian cancer. Leading the way in new options for ovarian cancer are poly (ADP-ribose) polymerase (PARP) inhibitors, which have shown improved efficacy for patients with ovarian cancer. Additionally, new indications for these targeted agents offer expanded options in the maintenance setting in varying lines of therapy.

Upon completion of this activity, participants will be able to:

  • Examine the clinical and socioeconomic burdens of ovarian cancer and the goals of maintenance that can be addressed by clinical pathways

  • Compare and contrast the safety, efficacy and tolerability profiles of PARP inhibitors and antibody-drug conjugates (ADCs) in the management of ovarian cancer

  • Analyze the role of PARP inhibitors as a first-line maintenance therapy for patients with BRCA-mutated advanced ovarian cancer

  • Assess the evolving role of antibody-drug conjugates (ADCs) in the management of recurrent platinum-sensitive ovarian cancer

  • Identify adverse events associated with current and emerging therapies, and select appropriate strategies to help ensure patient treatment adherence and optimum quality of life

  • Apply methods to enable optimal cost management of current and emerging treatments to be realized by multiple ovarian cancer stakeholders including managed care organizations
     

Faculty: Robert L. Coleman, MD, FACOG, FACS
Ann Rife Cox Chair in Gynecology
Department of Gynecologic Oncology and Reproductive Medicine
The University of Texas MD Anderson Cancer Center

Disclosure:

Dr. Coleman serves on an advisory board for Abbvie, Aravive, Astrazeneca, Clovis, Genmab, Genentech, and Tesaro. He has received grant/research support from Abbvie, Astrazeneca, Clovis, Genmab, and Merck. His presentation has been peer reviewed for any bias.
  Planning Committee:
Bill Williams, MD has no relevant financial relationships to disclose.
Jeremy Williams has no relevant financial relationships to disclose.
Will Williams has no relevant financial relationships to disclose.
Jacqueline Cole, RN, MS, CMCN has no relevant financial relationships to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
The National Association of Managed Care Physicians (NAMCP) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category I creditsTM.

The American Association of Managed Care Nurses (AAMCN) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation (ANCC).

Nurses who complete this activity and achieve a passing score will receive 1 hour in continuing
nursing credit.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hour toward CMCN recertification requirements.

This presentation is supported by educational grants from
AstraZeneca LP, ImmunoGen, & Merck Sharp & Dohme Corp.

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue